Monday, July 15, 2024
    HomeHealthChanging our DNA: 'The age of human therapeutic gene editing is here'

    Changing our DNA: ‘The age of human therapeutic gene editing is here’

    While Rose spent her short life helping to break down the stigma attached to a devastating illness, geneticist David Liu has dedicated his career to developing ways to alter the genetic code that took her life at such a tender age.

    “That a single misspelling in her DNA ended Adalia’s life so early is a loss for all of us,” said Liu, a professor of chemistry and chemical biology and director of the Merkin Institute of Transformative Technologies in Healthcare at Harvard University.

    “I did not get the chance to meet Adalia before she passed away in January. But every progeria patient I have met has been warm, charming, articulate and profoundly inspiring,” Liu told CNN.

    In his Harvard lab, Liu and his team have invented new ways to repair mutated genes that are less damaging to DNA than prior technologies. One of his lab’s major innovations is a base editor, a tool that can correct misspellings in the four most common bases in DNA, Liu told an audience at Life Itself, a health and wellness event presented in partnership with CNN.

    “These misspellings in our DNA collectively caused thousands of disorders that affect hundreds of millions of people and their families,” Liu said.

    These four DNA bases — adenine (A), cytosine (C), guanine (G) and thymine (T) — form specific pairs that are always supposed to be matched with each other: A with T, and G with C.

    Last year Liu and his team used a base editor to tackle the misplaced genes of progeria in mice. He’s hopeful clinical trials for children with progeria could begin in the near future.

    “The base editor goes into the cells of the animal, looks for the mistake, which in progeria is a C to a T and changes the T back into a C,” said Liu, who is also vice-chair of faculty at the Broad Institute of MIT and Harvard, a biomedical and genomic research center in Cambridge, Massachusetts.

    Liu’s team further discovered that base editors worked especially well if you “nick” the unedited strand of the DNA double helix, coaxing the cell to copy the desired edit onto the second strand.

    “And that’s it. We never come back into the patient — it’s a one-time treatment that permanently fixes the mutation that causes the disease,” Liu said.

    Six months after announcing success with progeria, Liu and scientists at St. Jude Children’s Research Hospital announced they had used base editors to reverse sickle cell disease in mice.

    “The age of human therapeutic gene editing isn’t just coming. It’s already here,” Liu told the Life Itself audience.

    The next generation of gene editors

    Scientists edit genes by using enzymes that have been engineered to target a specific sequence in DNA, cut out the offending genetic material and insert replacement DNA. For decades, however, known methods of modifying our genetic code were clumsy, often missing their target or cutting too much or too little genetic material.

    What is CRISPR and why is it controversial?
    The arrival of CRISPR systems in the 1990s and specifically CRISPR-Cas-9 in 2013 heralded a new, more elegant way to edit genes. CRISPR uses what is called guide RNA to get the Cas-9 enzyme to a more precise spot on the DNA strand to make the cut.

    CRISPR-Cas9 evolved in bacteria to disrupt the genes of infecting viruses by cutting both strands of DNA, essentially shutting the gene down, Liu explained to the audience.

    After years of vetting, the US Food and Drug Administration approved CRISPR-Cas-9 in 2021 for use in human clinical trials for sickle cell disease. Clinical trials are also underway to test the safety of gene editing in a blood disorder called beta thalassemia, leber congenital amaurosis, which is a form of inherited childhood blindness, blood cancers leukemia and lymphoma, Type 1 diabetes, and HIV/AIDS, to name a few.
    In 2021, researchers reported they had successfully edited a rare, painful condition called transthyretin amyloidosis in six people with a single treatment. The fatal disease causes a protein called TTR to fold into clumps and attack the heart and nerves. The study, published in August, reported levels of TTR in some people declined by an average of 87% after treatment.
    A researcher performs a CRISPR-Cas-9 process at the Max-Delbrueck-Centre for Molecular Medicine in Berlin.

    Editing larger sequences of DNA

    Cutting a double helix to silence a gene, however, did not solve the problem of the many genetic diseases that need a computer-like “find and replace” solution, Lui told the audience.

    The discovery of base editors, which could convert one letter into another, solved only a part of that problem. What was needed was a editor which could accomplish larger, more complex edits to DNA that base editors could not.

    Enter the next generation: prime editing.

    Unethical experiments' painful contributions to today's medicine

    “An analogy I like to use is that the original CRISPR-Cas_9 is like scissors that cut DNA. Base editors are like pencils that precisely correct letters by changing them to one of four different letters,” Liu explained. “And prime editors are like molecular word processors that do a true search and replace of larger sequences.”

    Only a third of the 75,000 known “misspellings” that cause genetic disease can be corrected by base editors, Liu said. “But add in our prime editor, and between the two they can finally liberate us from being beholden to the vast majority of misspellings in our DNA,” he said.

    In tests using human cells grown in the lab, Liu’s team used prime editing to correct the genes responsible for Tay-Sachs disease, a fatal neurological disorder that attacks in the first few months of life. Children with Tay-Sachs typically die within a few years after symptoms begin.

    “We have to make sure all of these different technologies go through clinical trials very carefully,” Liu added. “But if they prove to be safe and efficacious, then one could imagine treating not just rare misspellings that cause grievous genetic diseases, but perhaps even treating gene variants we know contribute to terrible diseases like Alzheimer’s disease or high cholesterol.”

    In a 2019 blog post, former National Institutes of Health director Dr. Francis Collins called prime editing “revolutionary,” saying Liu and his team had “used their new system to insert new DNA segments up to 44 letters long and to remove segments at least 80 letters long.”

    However, Collins added, “It’s unclear if prime editing can insert or remove DNA that’s the size of full-length genes — which may contain up to 2.4 million letters.”

    Scientists have unlocked the vitamin D potential of tomatoes, study says

    Genetic editing will not be a solution for all of life’s illness, Liu cautioned. For example, infections and cancer cells are two areas that are not well matched for gene editing, because you would need to touch each cell to stop the illness.

    “But with many genetic diseases, we often only need to edit 20% or 30% of tissue to rescue the genetic disease,” Liu said. “That’s what we saw with progeria and sickle cell disease in mice. A little bit of editing can go a long way to rescue these diseases in animals, and we think in people as well.”

    Correction: An earlier version of this story incorrectly attributed comments by Liu as made during the Life Itself conference. They were from an interview.

    Correction: An earlier version of this story misstated the number of base pairs that make up human DNA.

    Update: This story has been updated to reflect Lui’s statements at the Life Itself event and clarify details from the original version.



    Please enter your comment!
    Please enter your name here

    - Advertisment -
    Google search engine

    Most Popular

    Recent Comments